Stock ZYME ZYMEWORKS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Zymeworks Inc.

Equities

ZYME

US98985Y1082

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
8.11 USD -5.15% Intraday chart for Zymeworks Inc. -6.46% -21.94%
Apr. 08 Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting CI
Apr. 04 Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
PR
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
GL
Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting
CI
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
GL
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
PR
Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer
CI
Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President
CI
Zymeworks Inc. Announces the Composition of the Committees
CI
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
GL
Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024
CI
Zymeworks Announces Participation in Upcoming Investor Conferences
GL
Wells Fargo Adjusts Price Target on Zymeworks to $14 From $12, Maintains Overweight Rating
MT
H.C. Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating
MT
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Zymeworks Inc., Q4 2023 Earnings Call, Mar 06, 2024
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
GL
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZYME Stock
  4. News Zymeworks Inc.